S&P 500   3,328.64 (+0.09%)
DOW   29,260.33 (+0.34%)
QQQ   225.49 (+0.40%)
AAPL   322.00 (+0.87%)
FB   221.12 (+0.62%)
MSFT   167.50 (+0.47%)
GOOGL   1,488.44 (+0.25%)
AMZN   1,893.25 (+0.46%)
CGC   24.72 (+0.65%)
NVDA   255.50 (+1.04%)
BABA   218.77 (-0.16%)
MU   59.36 (+0.25%)
GE   11.74 (-0.34%)
TSLA   568.27 (-0.69%)
AMD   52.44 (+1.41%)
T   38.59 (-0.10%)
ACB   2.06 (-0.48%)
F   9.04 (-1.09%)
NFLX   354.71 (+1.46%)
PRI   125.37 (-0.14%)
BAC   33.86 (-0.76%)
DIS   141.63 (-0.40%)
GILD   63.60 (-0.53%)
S&P 500   3,328.64 (+0.09%)
DOW   29,260.33 (+0.34%)
QQQ   225.49 (+0.40%)
AAPL   322.00 (+0.87%)
FB   221.12 (+0.62%)
MSFT   167.50 (+0.47%)
GOOGL   1,488.44 (+0.25%)
AMZN   1,893.25 (+0.46%)
CGC   24.72 (+0.65%)
NVDA   255.50 (+1.04%)
BABA   218.77 (-0.16%)
MU   59.36 (+0.25%)
GE   11.74 (-0.34%)
TSLA   568.27 (-0.69%)
AMD   52.44 (+1.41%)
T   38.59 (-0.10%)
ACB   2.06 (-0.48%)
F   9.04 (-1.09%)
NFLX   354.71 (+1.46%)
PRI   125.37 (-0.14%)
BAC   33.86 (-0.76%)
DIS   141.63 (-0.40%)
GILD   63.60 (-0.53%)
S&P 500   3,328.64 (+0.09%)
DOW   29,260.33 (+0.34%)
QQQ   225.49 (+0.40%)
AAPL   322.00 (+0.87%)
FB   221.12 (+0.62%)
MSFT   167.50 (+0.47%)
GOOGL   1,488.44 (+0.25%)
AMZN   1,893.25 (+0.46%)
CGC   24.72 (+0.65%)
NVDA   255.50 (+1.04%)
BABA   218.77 (-0.16%)
MU   59.36 (+0.25%)
GE   11.74 (-0.34%)
TSLA   568.27 (-0.69%)
AMD   52.44 (+1.41%)
T   38.59 (-0.10%)
ACB   2.06 (-0.48%)
F   9.04 (-1.09%)
NFLX   354.71 (+1.46%)
PRI   125.37 (-0.14%)
BAC   33.86 (-0.76%)
DIS   141.63 (-0.40%)
GILD   63.60 (-0.53%)
S&P 500   3,328.64 (+0.09%)
DOW   29,260.33 (+0.34%)
QQQ   225.49 (+0.40%)
AAPL   322.00 (+0.87%)
FB   221.12 (+0.62%)
MSFT   167.50 (+0.47%)
GOOGL   1,488.44 (+0.25%)
AMZN   1,893.25 (+0.46%)
CGC   24.72 (+0.65%)
NVDA   255.50 (+1.04%)
BABA   218.77 (-0.16%)
MU   59.36 (+0.25%)
GE   11.74 (-0.34%)
TSLA   568.27 (-0.69%)
AMD   52.44 (+1.41%)
T   38.59 (-0.10%)
ACB   2.06 (-0.48%)
F   9.04 (-1.09%)
NFLX   354.71 (+1.46%)
PRI   125.37 (-0.14%)
BAC   33.86 (-0.76%)
DIS   141.63 (-0.40%)
GILD   63.60 (-0.53%)
Log in

NASDAQ:HOOK - Hookipa Pharma Stock Price, Forecast & News

$13.70
-0.10 (-0.72 %)
(As of 01/24/2020 10:01 AM ET)
Add
Compare
Today's Range
$13.67
Now: $13.70▼
$14.37
50-Day Range
$7.48
MA: $10.64▼
$13.80
52-Week Range
$6.06
Now: $13.70▼
$14.76
Volume16,968 shs
Average Volume76,114 shs
Market Capitalization$295.78 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HOOK
Previous Symbol
CUSIPN/A
CIKN/A
Webhttp://www.hookipapharma.com/
Phone431-890-6360

Debt

Debt-to-Equity Ratio0.08
Current Ratio10.53
Quick Ratio10.53

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees56
Outstanding Shares21,590,000
Market Cap$295.78 million
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive HOOK News and Ratings via Email

Sign-up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:HOOK Rates by TradingView

(Ad)

Paul Mampilly correctly predicted every bull and bear market over the last two decades. He made millions. His new "Dow 100,000" prediction is his boldest yet. Even more stunning... Paul reveals how you could make millions as it unfolds.

Hookipa Pharma (NASDAQ:HOOK) Frequently Asked Questions

What is Hookipa Pharma's stock symbol?

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.21. The company had revenue of $2.04 million for the quarter, compared to the consensus estimate of $2.35 million. View Hookipa Pharma's Earnings History.

When is Hookipa Pharma's next earnings date?

Hookipa Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Hookipa Pharma.

What price target have analysts set for HOOK?

5 equities research analysts have issued twelve-month price objectives for Hookipa Pharma's shares. Their forecasts range from $15.00 to $23.00. On average, they anticipate Hookipa Pharma's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 38.7% from the stock's current price. View Analyst Price Targets for Hookipa Pharma.

What is the consensus analysts' recommendation for Hookipa Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hookipa Pharma.

Has Hookipa Pharma been receiving favorable news coverage?

Press coverage about HOOK stock has trended extremely negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hookipa Pharma earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near term. View News Stories for Hookipa Pharma.

Are investors shorting Hookipa Pharma?

Hookipa Pharma saw a increase in short interest in December. As of December 31st, there was short interest totalling 297,700 shares, an increase of 213.4% from the December 15th total of 95,000 shares. Based on an average daily volume of 89,700 shares, the short-interest ratio is currently 3.3 days. Approximately 2.6% of the company's shares are short sold. View Hookipa Pharma's Current Options Chain.

Who are some of Hookipa Pharma's key competitors?

What other stocks do shareholders of Hookipa Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Editas Medicine (EDIT), AT&T (T), Exxon Mobil (XOM), Gossamer Bio (GOSS), Axsome Therapeutics (AXSM), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Dominion Energy (D), Marathon Petroleum (MPC) and Pfizer (PFE).

Who are Hookipa Pharma's key executives?

Hookipa Pharma's management team includes the folowing people:
  • Mr. Joern Aldag, Pres, CEO & Director (Age 60)
  • Mr. Daniel Pinschewer, Founder & Chief Scientific Officer (Age 44)
  • Dr. Reinhard Kandera, CFO & Director (Age 50)
  • Mr. Anders Lilja Ph.D., Sr. VP of Technical Devel. (Age 46)
  • Mrs. Nina Waibel, Communications & Investor Relations Mang.

When did Hookipa Pharma IPO?

(HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager.

How do I buy shares of Hookipa Pharma?

Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hookipa Pharma's stock price today?

One share of HOOK stock can currently be purchased for approximately $13.70.

How big of a company is Hookipa Pharma?

Hookipa Pharma has a market capitalization of $295.78 million. Hookipa Pharma employs 56 workers across the globe.View Additional Information About Hookipa Pharma.

What is Hookipa Pharma's official website?

The official website for Hookipa Pharma is http://www.hookipapharma.com/.

How can I contact Hookipa Pharma?

Hookipa Pharma's mailing address is 350 Fifth Avenue 72nd Floor Suite 7240, New York NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected]


MarketBeat Community Rating for Hookipa Pharma (NASDAQ HOOK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  65
MarketBeat's community ratings are surveys of what our community members think about Hookipa Pharma and other stocks. Vote "Outperform" if you believe HOOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Featured Article: Why do companies engage in swaps?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel